Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Deubiquitylating enzymes in neuronal health and disease

Abstract

Ubiquitylation and deubiquitylation play a pivotal role in protein homeostasis (proteostasis). Proteostasis shapes the proteome landscape in the human brain and its impairment is linked to neurodevelopmental and neurodegenerative disorders. Here we discuss the emerging roles of deubiquitylating enzymes in neuronal function and survival. We provide an updated perspective on the genetics, physiology, structure, and function of deubiquitylases in neuronal health and disease.

Facts

  • Deubiquitylation is essential for neuronal growth, function, and survival.

  • Mutations in some DUBs are associated with neurodevelopmental and neurodegenerative disorders.

  • DUBs influence learning and memory by regulating synaptic plasticity.

  • DUBs affect neuronal vulnerabilities in stroke and neurodegenerative diseases.

Open questions

  • Do neuronal DUBs interact with different regulatory proteins or substrates compared to those in non-neuronal cells?

  • How does the brain spatial expression pattern of DUBs correlate with specific neuronal functions?

  • Do synaptic activities regulate DUB expression, function, and localization?

  • Can we identify and employ pharmacological modulators of DUBs to treat neurological disorders?

Introduction

Ubiquitylation plays a pivotal role in cellular homeostasis by regulating proteasomal and lysosomal degradation, protein quality control, cellular trafficking and localization, protein–protein interactions, and many other cellular functions (Fig. 1a)1,2,3. The conjugation of ubiquitin to a target protein usually involves three types of enzyme: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3)1. First, a catalytic cysteine of E1 forms a thioester bond with the C-terminus (G76) of ubiquitin, in an ATP-dependent reaction: namely, adenylation4,5. Ubiquitin is then transferred to a cysteine of E26,7,8. Finally, E3 associates with specific target proteins and promotes the transfer of ubiquitin to a lysine (K) residue of the target (Fig. 1b)1,3,6,9. The monoubiquitylated target may undergo further ubiquitylation to form a multi-monoubiquitylated protein or the primed ubiquitin can be furthered ubiquitylated to form a chain known as a polyubiquitylated target. All seven lysine residues of ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) and its N-terminus (Met1) may serve as ubiquitylation sites, leading to the formation of homotypic or heterotypic (branched) ubiquitin chains (Fig. 1c, d)1,3. These different ubiquitylation forms are recognized by a large variety of ubiquitin receptors that contain ubiquitin-binding domains and decode the signals into different cellular responses in a spatio-temporal manner10,11,12,13,14 (Fig. 1a). Ubiquitylation is a highly dynamic process and is typically short-lived due to degradation or to the function of deubiquitylating enzymes (DUBs) that rapidly and efficiently reverse the signal15,16,17 (Fig. 1d). Interestingly, the transient characteristics of ubiquitin signals are also achieved by the association of E3s (or E2s) with DUBs18,19. In some cases, this association was even developed to a fusion of an E3 with a DUB to edit the ubiquitylation signal20.

Fig. 1: The ubiquitin system: ubiquitylation, ubiquitin recognition, and deubiquitylation.
figure1

a A schematic representation of ubiquitylation/deubiquitylation events of target proteins and the cellular outcome. b The ubiquitylation cascade by three types of enzyme: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). c The seven lysine residues and the N-terminal methionine (M1) are projected on the structure of ubiquitin (PDB code 1UBQ98). d Principles of substrate recognition and ubiquitin cleavage by DUBs. e. Families of DUBs classified by sequence homology of their catalytic domains.

In humans, approximately 90 DUBs are known, with diverse patterns of expression and abundance in different tissues16. Some DUBs recognize and cleave the peptide bond between the C-terminus of ubiquitin and the N-terminus of target proteins as a result of N-terminal ubiquitylation or linear ubiquitin chains21 (Fig. 1d), while other DUBs are restricted to the iso-peptide bonds as a result of the conjugation of ubiquitin to the side-chain residue of (usually) lysine at the targeted protein15,16 (Fig. 1d). A considerable number of DUBs are very large proteins that have acquired several domains during the course of evolution and display multifunctional activities22,23. DUBs recognize the C-terminus of ubiquitin and in many cases also specific residues in the vicinity of the conjugation site, which could be on the targeted protein or on ubiquitin itself in the case of cleavage within a polyubiquitin chain15,16. They can also possess several ubiquitin binding spots (or domains) that interact with the isoleucine 44 (I44) hydrophobic patch and/or other patches on ubiquitin in order to distinguish between different ubiquitin chains. DUBs are broadly classified as cysteine proteases or metalloproteases (Fig. 1e). The cysteine proteases include ubiquitin-specific proteases (USPs), ovarian tumor proteases (OTUs), ubiquitin C-terminal hydrolases (UCHs), Josephins, motif interacting with Ub-containing novel DUB family (MINDY), and Zn-finger and UFSP domain protein (ZUFSP). The zinc metalloproteases include JAB1/MPN/MOV34 (JAMMs).

The plethora of ubiquitin signals in the mammalian brain supports the idea that this type of post-translational modification is essential for neuronal function24,25. Because DUBs regulate ubiquitylation signals16, they play an important role in maintaining protein homeostasis (proteostasis) and signaling in neurons. Indeed, accumulating evidence in humans and in mice suggests that mutations in specific DUBs may lead to neurological abnormalities (Table 1). These studies promote our understanding of ubiquitin signaling in the development, function, and degeneration of the mammalian brain.

Table 1 Identified DUB mutations in humans with neurological disorders and proposed mechanisms in neuronal homeostasis.

Synaptic plasticity and neurodevelopment

The excitatory synapse comprises a postsynaptic density and a presynaptic terminus. The latter is loaded with synaptic vesicles containing the neurotransmitter glutamate26. Glutamate released from the axonal presynaptic terminus binds to glutamate receptors at the postsynaptic density of the dendrite. This leads to ion influx, activation of voltage-gated ion channels, and activation of the specific signaling pathways leading to neuronal transmission26. DUBs are known to play diverse roles at the postsynaptic density. These include controlling the turnover of specific proteins involved in synaptic function, as well as ensuring monomeric ubiquitin availability (Fig. 2).

Fig. 2: An emerging model for DUB regulation of synaptic plasticity.
figure2

Activation of postsynaptic glutamate receptors controls neuron excitability. The postsynaptic density is enriched with a growing number of DUBs that antagonize E3-ligases and remove ubiquitin (Ub) chains, thereby protecting designated substrates from degradation by the lysosomes or the proteasome. Certain DUBs regulate the degradation and surface localization of the glutamate receptor, AMPAR. Moreover, a number of DUBs support the formation and function of the glutamatergic synapse by regulating the levels of scaffold proteins (SHANK and Ankyrin) and the leptin receptor (LepR). DUBs with yet unknown substrates are labeled with a question mark (?). The Ub symbol in this image indicates a polyubiquitin chain.

DUB control of glutamate receptors

The postsynaptic density of the glutamatergic synapses is enriched with receptors and scaffolding proteins26. Members of one of the receptor families, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), enable excitatory synaptic transmission in the brain. Synaptic plasticity, which is important for learning and memory, is influenced by the strength of synaptic transmission, which in turn correlates with the density of AMPARs at the synapse26. The amount of AMPARs on the cell surface is regulated by ubiquitylation and deubiquitylation. Both monoubiquitylation and polyubiquitylation are likely to exert an internalization signal27. However, the role of monoubiquitylation in lysosomal degradation of glutamate receptors is less clear in comparison to polyubiquitylation. For example, AMPARs undergo Lys63 polyubiquitylation by the HECT E3 ligase, NEDD4, resulting in AMPAR endocytosis and degradation in hippocampal neurons28,29. Conversely, the USP family member, USP46, is present in postsynaptic density fractions of hippocampal neurons and stabilizes cell-surface AMPAR levels by cleaving the Lys63 polyubiquitin chains30. USP46 knockout mice showed behavioral abnormalities, such as decreased exploratory behavior, which might be correlated with mental disorders31.

In the context of Alzheimer’s disease, it was recently shown that the aggregate-prone protein amyloid‐β induces NEDD4‐dependent AMPAR degradation, leading to synaptic weakening32. Moreover, amyloid‐β-exposed neurons showed an increased expression of NEDD4 and decreased levels of USP4632. This could suggest an antagonistic function of USP46 (in regard to NEDD4) in AMPAR recycling.

USP46, as well as other USPs, contains a region consisting of three subdomains: termed palm, fingers, and thumb33 (Fig. 3a). The active site that comprises the catalytic triad (residues Cys, Asp, and His) is located at the interface between the palm and thumb (Fig. 3a). The fingers subdomain binds and coordinates the cleaving ubiquitin in such a manner that its C-terminus becomes located in the active site33. In various USPs this binding induces conformational changes that realign the catalytic triad residues for catalysis17. The activity of USPs is regulated by several mechanisms, including the allosteric rearrangement of the catalytic triad33, post-translational modifications34, subcellular localization35, and/or by noncovalent interaction with other regulatory proteins such as WD40-repeat (WDR)36.

Fig. 3: Structure of USP46 and its regulatory partners.
figure3

a The structure of USP46 subdomains. Residues of the catalytic triad located at the interface between the palm and the thumb subdomains are shown as green sticks (PDB code 5L8H40). b A model of USP46 complex based on superposition of the structures of USP46 with covalent ubiquitin (Ub-VME) (PDB code 5L8H40) with the non-covalent complex of USP46:WDR20:WDR48 (PDB code 6JLQ39).

Interestingly, the Caenorhabditis elegans homologs of WDR20 and WDR48 (also known as UAF1) can bind to and activate USP46. The WDR protein effects on USP46 increase the stability of GLR-1, the C. elegans homolog of AMPAR37. We superimposed the crystal structures of USP46 in a non-covalent complex with WDR20 and WDR48 together with the covalent USP46–ubiquitin complex. This revealed that the two β-propellers bind remotely from the active site and do not interact with ubiquitin (Fig. 3b). It seems that, unlike the binding of other β-propeller proteins that realign the active site of DUBs, binding to the convex side of USP46 stimulates its activity via stabilization and a prolonged residence time of the ubiquitylated substrates38. Indeed, it has been demonstrated that the binding of WDR20 and WDR48 synergistically activates USP4639. Similarly, Sixma and colleagues demonstrated that WDR48 regulates USP12 by a two-step binding mechanism40.

Another USP member, USP8, is present in both somatic and dendritic compartments in hippocampal neurons and is also enriched in postsynaptic density fractions, suggesting that the protein might influence synaptic strength41. Upon N-methyl- d-aspartic acid receptor (NMDAR) activation, USP8 is dephosphorylated and facilitates the recycling of internalized AMPARs41. Recently, USP8 was also reported to be regulated by the hormone leptin that acts in the hippocampus42. Bland and colleagues suggested that leptin increases the expression of USP8, which in turn deubiquitylates the leptin receptor by cleaving Lys48-ubiquitin chains, among other (still unknown) chain types. This process is likely to be related to increased leptin receptor surface localization and synapse formation42.

DUBs and scaffolding proteins at the postsynaptic density

SHANK proteins are scaffolding proteins of the postsynaptic glutamatergic synapses43 that bind to a variety of proteins at the postsynaptic density of excitatory synapses44. There are three main classes of SHANK proteins: namely, SHANK1, SHANK2, and SHANK3, and mutations in these proteins correlate with neurodevelopmental disorders. For example, mutations that alter SHANK3 protein levels were described in Phelan-McDermid syndrome, autism spectrum disorders, and schizophrenia44. A number of patients with high-functioning autism and schizophrenia show duplication of SHANK344. USP8 stabilizes the levels of SHANK1 and SHANK3 proteins in hippocampal neurons, and thus increases the dendritic spine density43. USP8 also protects SHANK1 and SHANK3 from proteasomal degradation by cleaving the associated polyubiquitin chains43. Interestingly, SHANK3 was shown to regulate the striatal synaptic abundance of a USP member, CYLD, which specifically cleaves linear and Lys63-ubiquitin chains45,46,47. The substrates for deubiquitylation by CYLD at the postsynaptic density still remain unknown.

One of the approaches to identifying specific substrates for DUBs is a yeast two-hybrid screen. Some DUBs reveal a specific interaction with their substrates regardless of the ubiquitylation state (Fig. 1d) This increases the probability of finding these substrates in the yeast-two-hybrid system. Yoon and colleagues utilized this approach to identify the USP member USP9X as a DUB for the protein ankyrin-G in cortical neurons48. The function of ankyrin-G is to link plasma membrane proteins to the cytoskeleton49. Variants in the ANK3 gene encoding ankyrin-G are associated with neurodevelopmental disorders, and ankyrin-G is enriched in postsynaptic density fractions and facilitates synapse formation48. USP9X cleaves polyubiquitin chains in ankyrin-G and protects ankyrin-G from ubiquitylation-dependent proteasomal degradation. Interestingly, USP9X phosphorylation enhances the DUB activity towards ankyrin-G and correlates with spine development48. This is important since loss-of-function mutations in the USP9X are correlated with intellectual disability, autism, and epilepsy50.

Another study by Paemka and colleagues demonstrated the nuclear receptors PRICKLE1/2 as targets for USP9X-mediated deubiquitylation51. Mutations in the genes coding for PRICKLEs are associated with seizures in humans and in mice, and the levels of PRICKLE2 were greatly reduced in mice lacking USP9X in the forebrain51. It has been demonstrated that PRICKLE is ubiquitylated by the ubiquitin E3 ligases HECT/NEDD4 family members SMURF1/2 for proteasome-mediated degradation52. Intriguingly, USP9X was also shown to interact with SMURF1 and to protect it from ligase activity-dependent self-degradation53. The association of DUBs with NEDD4 members is predicted to regulate their activity either by preventing their degradation or by reactivating their self-ubiquitylated basal inactive state29. However, USP9X directly interacts with PRICKLE1 and PRICKLE2 and cleaves their conjugated polyubiquitin chains51. The mechanism of PRICKLE’s regulation by USP9X thus seems to be highly complex and requires further mechanistic studies. Degrasyn (also known as WP1130) was serendipitously identified in a screen for JAK2 inhibitors. It pharmacologically inhibits the DUBs UCH37, USP5, USP14, and USP9X54. Degrasyn suppresses the seizure phenotype in PRICKLE mutant flies, suggesting that USP9X is involved in seizures and that modulating its activity might have potential as an anti-seizure modality51.

Microdeletions in 15q13.3 are rare conditions associated with intellectual disability and seizures55,56. One of the six genes commonly deleted in such neurological disorders is the OTU member OTUD7A, which cleaves Lys11-ubiquitin chains55,56,57. OTUD7A null mice possess a reduced number of functioning excitatory synapses and exhibit developmental delay. OTUD7A is localized to dendritic spines and is a positive regulator of dendritic spine density in cortical neurons55,56. It would be interesting to determine whether OTUD7A is selective for cortical synapses or also exerts its effects on hippocampal neurons.

Overall, it has become apparent that synaptic plasticity is regulated, at least in part, by a growing number of DUBs that form a network of key proteins responsible for regulating ubiquitin in the synapse. The contribution of DUBs in the postsynaptic density fraction to synaptic plasticity is depicted in Fig. 2.

Other neurodevelopmental mechanisms mediated by DUBs

The formation of a functional excitatory synapse requires neuronal growth and maturation. These early stages in neuronal development are also regulated by certain DUBs (Table 1). The USP member USP16 regulates cell-cycle progression through deubiquitylation of histone H2A58. The self-renewal capacity of hematopoietic stem cells and neural progenitors is antagonized by USP16, which is triplicated in patients with Down’s syndrome58. Moreover, USP9X plays an important role in the self-renewal of hippocampal stem cells59. Interestingly, studies in USP9X knockout mice support the presence of an additional role for USP9X in the normal morphological development of the adult dentate gyrus59.

Other processes regulated by deubiquitylation, and linked to neurodevelopmental disorders, are those of cellular protein trafficking and endosomal recycling. In order to identify the probable DUBs involved, Hao and colleagues utilized tandem affinity purification of a specialized endosomal ubiquitin E3 ligase regulator, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS)60. This approach enabled them to identify the USP member USP7 as a regulator of WASH polyubiquitylation and endosomal F-actin levels in hypothalamic neurons60. WASH is an actin nucleation promoting factor essential for endosomal protein recycling61. In this context, loss-of-function mutations of USP7 were associated with intellectual disability and autism spectrum disorder that might result in part from defects in brain endosomal recycling60.

Role of DUBs in neurodegeneration and stroke

A number of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and polyglutamine diseases, are associated with brain accumulation of toxic aggregate-prone proteins, which affect neuronal function and eventually lead to neuronal loss62,63. Another impaired brain condition, though of a very different kind, is ischemic stroke, which is characterized by disruption of the blood supply to the brain and vascular thrombus formation63. Such trauma to the brain causes neuronal death and is responsible for the subsequent neurological abnormalities, such as locomotor dysfunctions and impaired memory and learning skills63. Accumulating genetic and cellular evidence indicates a role for DUBs in neurodegeneration and stroke (Fig. 4).

Fig. 4: DUB involvement in neuron survival under normal conditions and in response to stressors.
figure4

The cell survival tyrosine receptor kinase B (TrkB) is activated by BDNF and is ubiquitylated by E3-ligases for degradation. The DUB, UCH-L1, deubiqutylates TrkB and thereby regulates TrkB levels and surface localization. The accumulation of aggregate-prone proteins (for example, α-synuclein) and damaged mitochondria are associated with neuronal loss in neurodegenerative diseases, such as Parkinson’s disease. These proteins and damaged mitochondria are ubiquitylated by E3-ligases (for example, parkin ubiquitylation of damaged mitochondria) and are engulfed by autophagosomes for degradation in the lysosome. A number of DUBs antagonize autophagy-mediated degradation of damaged mitochondria (USP30 and USP15) and α-synuclein (USP8). Moreover, other DUBs (ataxin-3, USP14 and USP12) are involved in promoting neuronal autophagy. DUBs with yet unknown substrates are labeled with a question mark (?). The Ub symbol in this image indicates a polyubiquitin chain.

Brain pathologies and proteasome-resident DUBs

The proteasomal DUBs comprise three types of enzyme—USP14, UCHL5, and metalloprotease, PSMD14/RPN1164. These appear to be important for brain development. Depletion of the UCH family member, UCHL5, causes prenatal lethality in mice, with disorganized neuronal growth most evident in the areas of the forebrain, cerebellum, and midbrain65. Similarly, a genetic lesion in the gene encoding the USP member USP14 causes ataxia in mice, which is characterized by decreased brain development and reduced levels of free synaptic ubiquitin66,67. Moreover, USP14 was also shown to inhibit proteasome-mediated degradation by cleaving ubiquitin chains conjugated to substrates68. In this context, pharmacological inhibition of USP14 was neuroprotective, resulting in dose–response- increased proteasome activity and enhanced clearance of a number of toxic aggregate-prone proteins that have been implicated in neurodegenerative diseases68,69. Another example of neuroprotection was found in stroke, in which decreased expression of USP14 by microRNA or miR-124, as well as USP14 inactivation, was linked to neuron survival in the post-ischemic mouse brain69.

DUBs and neuronal autophagy

Autophagy is a catabolic cell survival pathway that protects neurons from various stressors, such as aggregate-prone proteins and damaged mitochondria70. Upregulation of autophagy demonstrated beneficial effects in cell and animal models of polyglutamine, Alzheimer’s, and Parkinson’s diseases70. The process starts with the formation of autophagosomes, which engulf cytoplasmic proteins and organelles and direct them for degradation in the lysosome. One of the complexes involved in autophagosome initiation comprises beclin 171. USP14 negatively regulates autophagy by cleaving the Lys63-ubiquitin chains and deubiquitylating beclin 171. Remarkably, inhibiting USP14 resulted in an increase in both autophagy and proteasome activity, suggesting that USP14 could represent an attractive potential therapeutic target in neurodegenerative diseases68,71.

Ataxin-3, which is a member of the Josephine DUB family, has a preference for longer polyubiquitin chains and is known to interact with several ubiquitin ligases implicated in proteasome-mediated degradation72. However, it now appears that the functions of ataxin-3 extend beyond the proteasome system to other signaling pathways, including DNA damage and autophagy72,73. A polyglutamine expansion mutation in ataxin-3 causes spinocerebellar ataxia type 3 (SCA3), thereby providing a further link between ubiquitin-dependent protein quality control mechanisms and neurodegeneration (Table 1)72,74. The mutant ataxin-3 seems less effective than the wild type in deubiquitylating and therefore stabilizing beclin 175. This may explain the reduced beclin 1 levels and compromised autophagy observed in the brains of SCA3 patients and related mouse models74. As a corollary, overexpression of beclin 1 can stimulate the autophagic flux and promote clearance of the mutant ataxin-3 in brains of SCA3 mouse models. This process was associated with a reduction in SCA3-related behavior and neuropathology74.

Another DUB that regulates autophagy in neurons is USP12. Aron and colleagues examined the mechanism of action of USP12 in primary neurons and stem cell-derived neuron models of Huntington’s disease76. They found that USP12 protects against mutant huntingtin toxicity, as evidenced by analyzing distinctive neuronal morphology and the disruption of plasma membrane as indications of cell death. Interestingly, the catalytic activity of USP12 appeared not to be required for the induction of autophagy flux and clearance of mutant huntingtin in these neurons76. These findings imply that a non-catalytic function of DUBs might be important for neuronal function. This could be of potential relevance when considering how to modulate the function of a DUB by targeting its catalytic site.

The USP family member USP8 is found in Lewy bodies, a neuropathological hallmark of Parkinson’s disease composed of lipids and α-synuclein inclusions77,78. Aggregate-prone α-synuclein is toxic to neurons and can be cleared via autophagy70. Autophagosomes engulf aggregate-prone proteins (e.g., mutant huntingtin, mutant ataxin-3, and α-synuclein) for degradation in the lysosome via autophagy receptor recognition of ubiquitin chain labeling, such as Lys63 chains70. USP8 interacts with α-synuclein and cleaves Lys63 ubiquitin chains in α-synuclein, thereby inhibiting α-synuclein degradation in the lysosome78.

In addition to their role in autophagy, there are a number of DUBs that facilitate or antagonize mitophagy, a specialized autophagy pathway that mediates the clearance of damaged mitochondria by lysosomes79. If left uncleared, defective mitochondria can represent a source of oxidative stress and DNA damage that has been related to Parkinson’s disease79. USP8 can facilitate mitophagy by regulating the E3-ubiquitin ligase, parkin80. The removal of Lys6- ubiquitin chains by USP8 stabilizes parkin levels in the cortical neurons, enhances parkin recruitment to damaged mitochondria, and ubiquitylates certain mitochondrial proteins (e.g., VDAC1 and TOMM20). USP8 appears to have opposing roles in the context of Parkinson’s disease by either stabilizing α-synuclein levels or promoting parkin-mediated mitophagy78,80.

Parkin-mediated mitophagy is antagonized by the USP family members USP30, USP15, and the short form of USP35 (Fig. 4)81,82,83. Since some of the studies exploring parkin-antagonizing DUBs were performed in non-neuronal cells with expression vectors, there has been an utmost need to develop neuronal relevant models to explore these DUBs. By utilizing induced neurons derived from embryonic stem cells, Harper and colleagues recently described the landscape of parkin-dependent ubiquitylation, and USP30-dependent deubiquitylation on mitochondria in these neurons84. USP30 is a mitochondrial resident enzyme, but is also found in the oxidative organelles, peroxisomes81,85. USP30 can process diverse polyubiquitin chain types and was found to be highly efficient in cleaving Lys6- ubiquitin chains86.

The special case of UCH-L1

Ubiquitin C-terminal hydrolase L1 (UCH-L1), which belongs to the UCH DUB family, is enriched in the brain. UCH-L1 knockout mice exhibited neurodegeneration with aberrant synaptic structure and activity that could be attributed to reduced levels of free monomeric ubiquitin, since overexpression of ubiquitin in UCH-L1-deficient neurons restored the normal synaptic structure87,88. These results suggest that UCH-L1 plays an essential function in regulating ubiquitin homeostasis at the neuronal synapses88. In humans, UCH-L1 mutations are linked to neurodegenerative diseases, including spinocerebellar ataxia and Huntington’s disease, where the UCH-L1 polymorphism is linked to age at onset89,90. Moreover, UCH-L1 is downregulated in patients with Parkinson’s and Alzheimer’s diseases91. The functions of UCH-L1 are still enigmatic. It has been shown that UCH-L1 functions both as a DUB and as a ligase that extends Lys63-polyubiquitin chains on α-synuclein92. The ubiquitin ligase activity is enhanced by oligomerization of the enzyme92.

Boudreaux and colleagues demonstrated that, like certain other DUBs, the active site of apo UCH-L1 is misaligned with the canonical catalytic triad (Fig. 5)93. They found that ubiquitin binding induces conformational changes that reorganize the enzyme active site into an active form. Superposition of the apo and the covalent ubiquitin bound structures demonstrated active site rearrangement as a consequence of the ubiquitin binding. Specifically, ubiquitin residues L8 and T9 push F214 of UCH-L1 towards F53, and the latter induces a new rotamer (other preferred structure) for H161 of the catalytic triad (Fig. 5a). This movement considerably reduces the distance between H161 and the catalytic C90 (from 7.8 to 4.1 Å). Interestingly, Boudreaux and colleagues also determined the structures of S18Y and I93M UCH-L1 mutants in covalent complex with ubiquitin at C90 (Fig. 5b)93. These mutants are associated with the risk to develop Parkinson’s disease in a contrasting manner. The I93M is a dominant mutation, which increases disease risk, while S18Y is a disease protective variant92. The structures show that the catalytic residues are aligned with a wild-type active triad (Fig. 5b). Nevertheless, isoleucine93 (I93) is located close to the active site and its substitution to methionine probably interferes with hydrolytic activity. However, serine18 (S18) is a surface residue located far from the active site (Fig. 5b) and therefore its substitution to tyrosine is not likely to interfere with hydrolytic activity per se. Strikingly, Liu and colleagues demonstrated that wild-type UCH-L1 forms dimers with a significant ligase activity; however, the S18Y variant decreases UCH-L1 dimerization, and consequently reduces ligase activity for α-synuclein92. They speculated that this phenomenon reduces susceptibility to Parkinson’s disease, and it is still unknown how UCH-L1-mediated ubiquitylation/deubiquitylation affects α-synuclein toxicity.

Fig. 5: Structures of wild type and Parkinson’s disease-associated variants of UCH-L1.
figure5

a Superposition of the structures of wild-type apo and covalent bound ubiquitin to UCH-L1 is shown (PDB code 3KW593). Active site rearrangement and activation is due to ubiquitin binding. b Structures of the Parkinson’s disease variants, S18Y and I93M, are shown (PDB codes 3IFW and 3KVF) in comparison to the structure of wild-type UCH-L1 in complex with covalent ubiquitin.

Our current knowledge of more substrates of UCH-L1 in neurons is limited. Brain-derived neurotrophic factor (BDNF) activation of tyrosine receptor kinase (Trk) regulates neuron survival and synaptic plasticity. Moreover, Trk neurotrophin receptors are regulated by ubiquitin modifications94. Recently, Guo and colleagues showed that UCH-L1 interacts with tyrosine receptor kinase B (TrkB)95. UCH-L1 mediates the deubiquitylation of TrkB by cleaving ubiquitin (probably polyubiquitin chains) and thereby inhibits TrkB degradation. These effects also correlate with the regulation of trafficking of surface TrkB in hippocampal neurons and BDNF-TrkB signaling95(Fig. 4).

Future perspectives

It is generally accepted that alterations in the brain proteostasis network are linked to neurodegenerative and neurodevelopmental disorders. Recent progress on the underlying mechanisms suggests DUBs as regulators of proteostasis in neurons. Deubiquitylation appears to be a common signaling mechanism controlling synaptic plasticity, which is disrupted by DUB-associated neurodevelopmental mutations at the postsynaptic density. Since the accumulation of polyubiquitin chains triggers presynaptic assembly and growth96, it is plausible to assume that DUBs act on the presynaptic components. However, our knowledge regarding presynaptic ubiquitin regulation is still limited compared to that regarding postsynaptic density, and thus warrants further investigation.

Another open question relates to how the different DUBs coordinate with each other to ensure proper neuron function and response to stressors, such as aggregate-prone proteins and oxidative stress accumulation during aging. In particular, relating DUB mechanisms to spatial expression patterns in the mammalian brain might provide important information to answer this question. Such an analysis was recently performed for USP family members in granule neurons of the cerebellum97. These results may assist in targeting specific DUBs in brain pathologies involving differential neuronal vulnerabilities. In conclusion, we believe that future research into ubiquitin signaling holds great promise towards a better understanding of neuron homeostasis mechanisms, with the potential to design new therapeutic targets for various brain diseases.

References

  1. 1.

    Kwon, Y. T. & Ciechanover, A. The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem Sci. 42, 873–886 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818–822 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Swatek, K. N. & Komander, D. Ubiquitin modifications. Cell Res. 26, 399–422 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Ciechanover, A., Heller, H., Katz-Etzion, R. & Hershko, A. Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc. Natl Acad. Sci. USA 78, 761–765 (1981).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Schulman, B. A. & Harper, J. W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 10, 319–331 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 258, 8206–8214 (1983).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Ye, Y. & Rape, M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 10, 755–764 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Jentsch, S., McGrath, J. P. & Varshavsky, A. The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzyme. Nature 329, 131–134 (1987).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Zheng, N. & Shabek, N. Ubiquitin ligases: structure, function, and regulation. Annu. Rev. Biochem. 86, 129–157 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Hurley, J. H., Lee, S. & Prag, G. Ubiquitin-binding domains. Biochem J. 399, 361–372 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Deng, Z. et al. Autophagy receptors and neurodegenerative diseases. Trends Cell Biol. 27, 491–504 (2017).

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Shi, Y. et al. Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome. Science 351, aad9421 (2016).

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Keren-Kaplan, T. et al. Structure of ubiquitylated-Rpn10 provides insight into its autoregulation mechanism. Nat. Commun. 7, 12960 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Keren-Kaplan, T. & Prag, G. Purification and crystallization of mono-ubiquitylated ubiquitin receptor Rpn10. Acta Crystallogr. Sect. F. 68, 1120–1123 (2012).

    CAS  Article  Google Scholar 

  15. 15.

    Mevissen, T. E. T. & Komander, D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev. Biochem. 86, 159–192 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Clague, M. J., Urbe, S. & Komander, D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat. Rev. Mol. Cell Biol. 20, 338–352 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Sahtoe, D. D. & Sixma, T. K. Layers of DUB regulation. Trends Biochem Sci. 40, 456–467 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Fang, N. N., Zhu, M., Rose, A., Wu, K. P. & Mayor, T. Deubiquitinase activity is required for the proteasomal degradation of misfolded cytosolic proteins upon heat-stress. Nat. Commun. 7, 12907 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Wiener, R., Zhang, X., Wang, T. & Wolberger, C. The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature 483, 618–622 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694–699 (2004).

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Keusekotten, K. et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153, 1312–1326 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Prag, G., Greenberg, S. & Oppenheim, A. B. Structural principles of prokaryotic gene regulatory proteins and the evolution of repressors and gene activators. Mol. Microbiol. 26, 619–620 (1997).

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Marcotte, E. M. et al. Detecting protein function and protein-protein interactions from genome sequences. Science 285, 751–753 (1999).

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Abreha, M. H. et al. Quantitative analysis of the brain ubiquitylome in Alzheimer’s disease. Proteomics 18, e1800108 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. 25.

    Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell. 44, 325–340 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Huganir, R. L. & Nicoll, R. A. AMPARs and synaptic plasticity: the last 25 years. Neuron 80, 704–717 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Piper, R. C., Dikic, I. & Lukacs, G. L. Ubiquitin-dependent sorting in endocytosis. Cold Spring Harb Perspect Biol. 6, a016808 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  28. 28.

    Lin, A. et al. Nedd4-mediated AMPA receptor ubiquitination regulates receptor turnover and trafficking. J. Neurochem. 119, 27–39 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Attali, I. et al. Ubiquitylation-dependent oligomerization regulates activity of Nedd4 ligases. EMBO J. 36, 425–440 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Huo, Y. et al. The deubiquitinating enzyme USP46 regulates AMPA receptor ubiquitination and trafficking. J. Neurochem. 134, 1067–1080 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Imai, S., Kano, M., Nonoyama, K. & Ebihara, S. Behavioral characteristics of ubiquitin-specific peptidase 46-deficient mice. PLoS ONE 8, e58566 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Zhang, Y., Guo, O., Huo, Y., Wang, G. & Man, H. Y. Amyloid-beta induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer’s disease. J. Alzheimers Dis. 62, 1789–1801 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Hu, M. et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041–1054 (2002).

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Nicassio, F. et al. Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr. Biol. 17, 1972–1977 (2007).

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Row, P. E. et al. The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. J. Biol. Chem. 282, 30929–30937 (2007).

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Cohn, M. A. et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell 28, 786–797 (2007).

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Dahlberg, C. L. & Juo, P. The WD40-repeat proteins WDR-20 and WDR-48 bind and activate the deubiquitinating enzyme USP-46 to promote the abundance of the glutamate receptor GLR-1 in the ventral nerve cord of Caenorhabditis elegans. J. Biol. Chem. 289, 3444–3456 (2014).

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Yin, J. et al. Structural insights into WD-repeat 48 activation of ubiquitin-specific protease 46. Structure 23, 2043–2054 (2015).

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Zhu, H., Zhang, T., Wang, F., Yang, J. & Ding, J. Structural insights into the activation of USP46 by WDR48 and WDR20. Cell Disco. 5, 34 (2019).

    Article  CAS  Google Scholar 

  40. 40.

    Dharadhar, S., Clerici, M., van Dijk, W. J., Fish, A. & Sixma, T. K. A conserved two-step binding for the UAF1 regulator to the USP12 deubiquitinating enzyme. J. Struct. Biol. 196, 437–447 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Scudder, S. L. et al. Synaptic strength is bidirectionally controlled by opposing activity-dependent regulation of Nedd4-1 and USP8. J. Neurosci. 34, 16637–16649 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  42. 42.

    Bland, T. et al. USP8 deubiquitinates the leptin receptor and is necessary for leptin-mediated synapse formation. Endocrinology 160, 1982–1998 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Kerrisk Campbell, M. & Sheng, M. USP8 deubiquitinates SHANK3 to control synapse density and SHANK3 activity-dependent protein levels. J. Neurosci. 38, 5289–5301 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Guilmatre, A., Huguet, G., Delorme, R. & Bourgeron, T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev. Neurobiol. 74, 113–122 (2014).

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Komander, D. et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466–473 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Jin, C. et al. Shank3 regulates striatal synaptic abundance of Cyld, a deubiquitinase specific for Lys63-linked polyubiquitin chains. J. Neurochem. 150, 776–786 (2019).

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Thein, S., Pham, A., Bayer, K. U., Tao-Cheng, J. H. & Dosemeci, A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys. Res Commun. 450, 550–554 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Yoon, S. et al. Usp9X controls ankyrin-repeat domain protein homeostasis during dendritic spine development. Neuron 105, 506–521.e7 (2020).

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Bennett, V. & Lorenzo, D. N. Spectrin- and ankyrin-based membrane domains and the evolution of vertebrates. Curr. Top. Membr. 72, 1–37 (2013).

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Homan, C. C. et al. Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth. Am. J. Hum. Genet. 94, 470–478 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Paemka, L. et al. Seizures are regulated by ubiquitin-specific peptidase 9 X-linked (USP9X), a de-ubiquitinase. PLoS Genet. 11, e1005022 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. 52.

    Narimatsu, M. et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 137, 295–307 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Xie, Y. et al. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation. J. Biol. Chem. 288, 2976–2985 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Kapuria, V. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70, 9265–9276 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  55. 55.

    Yin, J. et al. Otud7a knockout mice recapitulate many neurological features of 15q13.3 microdeletion syndrome. Am. J. Hum. Genet. 102, 296–308 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Uddin, M. et al. OTUD7A regulates neurodevelopmental phenotypes in the 15q13.3 microdeletion syndrome. Am. J. Hum. Genet. 102, 278–295 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Mevissen, T. E. T. et al. Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. Nature 538, 402–405 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Adorno, M. et al. Usp16 contributes to somatic stem-cell defects in Down’s syndrome. Nature 501, 380–384 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Oishi, S. et al. Usp9x-deficiency disrupts the morphological development of the postnatal hippocampal dentate gyrus. Sci. Rep. 6, 25783 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Hao, Y. H. et al. USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder. Mol. Cell 59, 956–969 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Hao, Y. H. et al. Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination. Cell 152, 1051–1064 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10, S10–S17 (2004).

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  63. 63.

    Fan, J., Dawson, T. M. & Dawson, V. L. Cell death mechanisms of neurodegeneration. Adv. Neurobiol. 15, 403–425 (2017).

    PubMed  Article  PubMed Central  Google Scholar 

  64. 64.

    Lee, M. J., Lee, B. H., Hanna, J., King, R. W. & Finley, D. Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol. Cell Proteom. 10, R110 003871 (2011).

    Article  CAS  Google Scholar 

  65. 65.

    Al-Shami, A. et al. Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS ONE 5, e13654 (2010).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  66. 66.

    Wilson, S. M. et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet. 32, 420–425 (2002).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  67. 67.

    Chen, P. C. et al. The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J. Neurosci. 29, 10909–10919 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179–184 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Doeppner, T. R. et al. MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathol. 126, 251–265 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Menzies, F. M. et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015–1034 (2017).

    CAS  Article  Google Scholar 

  71. 71.

    Xu, D. et al. USP14 regulates autophagy by suppressing K63 ubiquitination of Beclin 1. Genes Dev. 30, 1718–1730 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    McLoughlin, H. S., Moore, L. R. & Paulson, H. L. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol. Dis. 134, 104635 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73.

    Herzog, L. K. et al. The Machado-Joseph disease deubiquitylase ataxin-3 interacts with LC3C/GABARAP and promotes autophagy. Aging Cell 19, e13051 (2020).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  74. 74.

    Nascimento-Ferreira, I. et al. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. Brain 136, 2173–2188 (2013).

    PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Ashkenazi, A. et al. Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature 545, 108–111 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Aron, R. et al. Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington’s disease. Nat. Commun. 9, 3191 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  77. 77.

    Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109 (2019).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  78. 78.

    Alexopoulou, Z. et al. Deubiquitinase Usp8 regulates alpha-synuclein clearance and modifies its toxicity in Lewy body disease. Proc. Natl Acad. Sci. USA 113, E4688–E4697 (2016).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  79. 79.

    Ryan, B. J., Hoek, S., Fon, E. A. & Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease. Trends Biochem Sci. 40, 200–210 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  80. 80.

    Durcan, T. M. et al. USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J. 33, 2473–2491 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Bingol, B. et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510, 370–375 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  82. 82.

    Cornelissen, T. et al. The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Hum. Mol. Genet. 23, 5227–5242 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Wang, Y. et al. Deubiquitinating enzymes regulate PARK2-mediated mitophagy. Autophagy 11, 595–606 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Ordureau, A. et al. Global landscape and dynamics of parkin and USP30-dependent ubiquitylomes in iNeurons during mitophagic signaling. Mol. Cell 77, e1110 (2020).

    Article  CAS  Google Scholar 

  85. 85.

    Marcassa, E. et al. Dual role of USP30 in controlling basal pexophagy and mitophagy. EMBO Rep. 19, e45595 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  86. 86.

    Cunningham, C. N. et al. USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat. Cell Biol. 17, 160–169 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  87. 87.

    Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23, 47–51 (1999).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  88. 88.

    Cartier, A. E. et al. Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J. Neurosci. 29, 7857–7868 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Naze, P., Vuillaume, I., Destee, A., Pasquier, F. & Sablonniere, B. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington’s disease. Neurosci. Lett. 328, 1–4 (2002).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  90. 90.

    Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101–106 (2000).

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Setsuie, R. & Wada, K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 51, 105–111 (2007).

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. & Lansbury, P. T. Jr The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111, 209–218 (2002).

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Boudreaux, D. A., Maiti, T. K., Davies, C. W. & Das, C. Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl Acad. Sci. USA 107, 9117–9122 (2010).

    CAS  PubMed  Article  Google Scholar 

  94. 94.

    Arevalo, J. C. et al. Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination. Neuron 50, 549–559 (2006).

    CAS  PubMed  Article  Google Scholar 

  95. 95.

    Guo, Y. Y. et al. Ubiquitin C-terminal hydrolase L1 (UCH-L1) promotes hippocampus-dependent memory via its deubiquitinating effect on TrkB. J. Neurosci. 37, 5978–5995 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Pinto, M. J. et al. The proteasome controls presynaptic differentiation through modulation of an on-site pool of polyubiquitinated conjugates. J. Cell Biol. 212, 789–801 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Anckar, J. & Bonni, A. Regulation of neuronal morphogenesis and positioning by ubiquitin-specific proteases in the cerebellum. PLoS ONE 10, e0117076 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  98. 98.

    Vijay-Kumar, S., Bugg, C. E. & Cook, W. J. Structure of ubiquitin refined at 1.8 A resolution. J. Mol. Biol. 194, 531–544 (1987).

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

We thank Margarita Galves and Hamutal Naftalie for initial discussions.

Ethics statement

No ethics approvals were required for this paper.

Funding statement

We are grateful for funding from the Azrieli Foundation (Faculty Fellowship) and Taube \Koret Global Collaboration in Neurodegenerative Diseases both awarded to A. Ashkenazi. We thank the Israel Science Foundation for the supporting grant 651/16 to G. Prag.

Author information

Affiliations

Authors

Contributions

A.A. and G.P. developed the rationale of the review. A..A., G.P., F.A.S., Y.B. and A.K. wrote the paper.

Corresponding authors

Correspondence to Gali Prag or Avraham Ashkenazi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Edited by F. Pentimalli

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Amer-Sarsour, F., Kordonsky, A., Berdichevsky, Y. et al. Deubiquitylating enzymes in neuronal health and disease. Cell Death Dis 12, 120 (2021). https://doi.org/10.1038/s41419-020-03361-5

Download citation

Further reading

Search

Quick links